Welcome to LookChem.com Sign In|Join Free
  • or

83905-01-5

Post Buying Request

83905-01-5 Suppliers

Recommended suppliersmore

Product FOB Price Min.Order Supply Ability Supplier
AzithromycinMaleate best price, best quality
Cas No: 83905-01-5
No Data 1 Kilogram 100 Kilogram/Day Tianjin Biochemical Pharmaceutical Co., Ltd Contact Supplier
Animal Drug Water Soluble Azithromycin 50-70% Content with 83905-01-5
Cas No: 83905-01-5
USD $ 1.0-2.0 / Gram 10 Gram 1000 Metric Ton/Year Hubei Jusheng Technology Co., Ltd., Contact Supplier
High purity 99% factory price Azithromycin powder
Cas No: 83905-01-5
USD $ 1.0-999.0 / Metric Ton 1 Metric Ton 20 Metric Ton/Month Sinoway Industrial Co., Ltd. Contact Supplier
USP Azithromycin Powder GMP Raw Material Azithromycin
Cas No: 83905-01-5
USD $ 110.0-120.0 / Kilogram 1 Kilogram 100 Metric Ton/Month HANWAYS CHEMPHARM CO.,LIMITED Contact Supplier
High quality Azithromycin
Cas No: 83905-01-5
USD $ 0.1-0.2 / Kilogram 1 Kilogram 1000 Kilogram/Month Binbo Biological Co., Ltd Contact Supplier
azithromycin/ 83905-01-5
Cas No: 83905-01-5
No Data 1 Kilogram Metric Ton/Day Zhengzhou Meitong Pharmaceutical Technology Co., Ltd. Contact Supplier
Azithromycin Dihydrate
Cas No: 83905-01-5
No Data 100 Gram Metric Ton/Day Hangzhou Dawn Ray Pharmaceutical Co.,Ltd Contact Supplier
Azithromycin factory supply CAS 83905-01-5
Cas No: 83905-01-5
USD $ 10.0-10.0 / Gram 1 Gram 10000 Kilogram/Month Hubei Vanz Pharm Co.,Ltd Contact Supplier
High purity Azithromycin CAS:83905-01-5
Cas No: 83905-01-5
USD $ 100.0-500.0 / Gram 1 Gram 99999 Gram/Year Hangzhou Dingyan Chem Co., Ltd Contact Supplier
High quality Azithromycin Usp supplier in China
Cas No: 83905-01-5
No Data No Data Metric Ton/Day Simagchem Corporation Contact Supplier

83905-01-5 Usage

The most commonly used antibiotics

Because the side effects of Azithromycin are less than Cephalosporins, now Azithromycin is the most commonly used antibiotics for bacterial infection-related diseases in our hospital clinic. This drug is a second generation semi-synthetic derivative of macrolide, whose structure is different from Erythromycin. It inserted a methyl-substituted nitrogen in 9a site of Erythromycin lactone ring, generating a 15-membered ring macrolide. The mechanism of action of Azithromycin is similar to Erythromycin. By binding to 50S subunit susceptible ribosome, Azithromycin inhibits protein synthesis which depends on RNA to show an antibacterial effect, retaining the antibacterial spectrum of typical Erythromycin. As for activity to chlamydia, Azithromycin is similar to Erythromycin. Compared with Erythromycin, antibacterial activity for gram-negative bacteria has been significantly improved, antibacterial activity for Haemophilus influenzae and Neisseria gonorrhoeae is more four times than Erythromycin, antimicrobial activity for Legionella bacteria is more about 2 times than Erythromycin, and antibacterial activity for Enterobacteriaceae is significantly stronger than Erythromycin. The MIC of most gram-negative bacteria is less than 1μg/ml. Staphylococcus aureus and Streptococcus pyogenes show cross-resistance on Azithromycin and Erythromycin. For toxoplasmosis and syphilis, Azithromycin also has a good role in the killing. Azithromycin is mainly used for respiratory tract infections, genitourinary tract infections, skin and soft tissue infections and sexually transmitted diseases which are caused by sensitive bacteria.

Pharmacokinetics

It is rapidly absorbed after oral administration, and its bioavailability is 37%. After a single oral dose of 0.5g, the peak time is 2.5 to 2.6 hours, peak plasma concentration (Cmax) is 0.4~0.45mg/L. This product is widely distributed in the body, and concentrations in each tissue are up to 10 to 100 times of the blood concentration over the same period. The plasma concentrations are high in macrophages and fibroblasts , the former can transport Azithromycin to inflammation sites. After a single dose administration of the product, elimination half-life of plasma concentration is 35 to 48 hours, more than 50% of the administered dose is excreted in the bile duct in original shape, and after 72 hours administration about 4.5% is excreted in the urine in original shape. With increasing plasma concentrations, serum protein binding rate of this product decreased. When the plasma concentration is 0.02 μg/mL, serum protein binding rate is 15%; when the blood concentration is 2 μg/mL, serum protein binding rate is 7%.

Antibacterial spectrum

1. Gram-positive aerobic bacteria, such as Staphylococcus aureus, Streptococcus pyogenes (A group β-hemolytic streptococcus), Streptococcus pneumoniae, α-hemolytic Streptococci (Streptococcus viridans group) and the other Streptococcus, Diphtheria (rodlike) bacteria. 2. Gram-negative aerobic bacteria, such as Haemophilus influenzae, Haemophilus parainfluenza, catarrhal bacteria, Acinetobacter, Yersinia, Legionella spp, Bordetella pertussis, parapertussis, Shigella, Pasteurella spp., Vibrio cholerae, Vibrio parahaemolyticus, Shiga topiramate o Aeromonas. The activities for Escherichia coli, Salmonella enteritidis, Salmonella typhi, Enterobacter, addicted to waterborne Aeromonas and Klebsiella are not the same, and sensitivity test is needed. 3. Anaerobic bacteria, such as Bacteroides spp., Clostridium perfringens, Lactococcus digestion, digestion Streptococcus, Fusobacterium, Propionibacterium acnes. 4. Sexually transmitted disease microorganisms, such as Chlamydia trachomatis, Treponema pallidum, Neisseria gonorrhoeae, Haemophilus Duke. 5. Other microorganisms, such as Borrelia burgdorferi (Lyme pathogens), Chlamydia pneumoniae, Mycoplasma hominis, Ureaplasma urea, bending genus, mononucleosis and Lee de bacilli. Azithromycin shows cross-resistance for Gram-positive bacteria with Erythromycin-resistant and various strains of Staphylococcus aureus with methicillin-resistant, and Gram-positive bacteria such as Proteus, Serratia, Morgan bacteria, Pseudomonas aeruginosa are usually resistant to Azithromycin.

Indications

This product is suitable for the treatment of the following symptoms of infection caused by susceptible bacteria: 1. For acute pharyngitis and acute tonsillitis caused by Streptococcus pyogenes and for nasosinusitis, acute otitis media, acute bronchitis, and acute exacerbation of chronic bronchitis caused by sensitive bacteria. 2. For pneumonia caused by Mycoplasma pneumonia, Streptococcus pneumonia and Haemophilus influenza. 3. For urethritis, cervicitis and pelvic inflammatory disease caused by chlamydia and non-multiple drug resistance Neisseria gonorrhoeae, and for simple genital infection caused by non-multiple drug resistance Neisseria gonorrhoeae (exclude co-infection of Misu spirochetes). 4. For skin and soft tissue infections caused by sensitive bacteria.

Dosing instructions

1. The oral administration of drug should be in the 1 hour before meals or 2 hours after meals. 2. Azithromycin injection should not be administered intramuscularly. Single intravenous infusion time should not be less than 60 minutes, and infusion concentration should not exceed 2mg/ml. 3. Solution preparation: Azithromycin is fully dissolved with the appropriate amount of water for injection, prepared a 100mg/ml solution. And then it is added into 250ml or 0.9% 500ml of sodium chloride injection or 5% glucose injection, finally formulated as 1-2mg/ml intravenous drip infusion. 4. If allergic reactions is happened during treatment, patients should be discontinued immediately. Like other antibiotics, superinfection symptoms caused by susceptible bacteria including fungi should be observed. If diarrhea symptom is appeared, it should be considered whether pseudomembranous colitis occur or not. In case of the establishment of the diagnosis, appropriate therapeutic measures should be took immediately, including maintenance of water and electrolyte balance, proteins supplement, etc. 5. If drug overdose reaction happens in medication, gastric lavage or general supportive therapy can be performed.

Usage and dosage

Adult General dose Oral administration 1. Community-acquired pneumonia: intravenous infusion for at least 2 days turning into oral administration, once 500 mg, 1 times a day, 7-10 day for a course. 2. For sexually transmitted diseases caused by Chlamydia trachomatis, Duke Haemophilus or sensitive Neisseria gonorrhoeae, only a single oral dose of 1g. 3. Pelvic inflammation disease: intravenous infusion for 1-2 days turning into oral administration, once 250 mg, 1 time a day, 7 day a course of treatment. Intravenous infusion 1.Community-acquired pneumonia: one 500mg, once a day, at least continuous medication for 2 days, followed by turning into oral administration. Usage and dosage see oral administration items. 2. Pelvic inflammatory disease: an adult once 500 mg, 1 times a day, 1-2 days of medication, using the drug for oral administration. Usage and dosage see oral administration items. Renal insufficiency dose Patients with mild renal insufficiency (creatinine clearance rate is greater than 40ml/min) are no need for dose adjustment. Hepatic insufficiency dose Patients with mild to moderate hepatic dysfunction are no need for dose adjustment. Elderly dosage: Usage and dosage is same as adults. Children General dose Oral administration 1. General infections: total dose for children is 30 mg/kg, once 10 mg/kg, 1 times a day, consecutive administration for 3 days; or the first day 10 mg/kg, 2-5 days, once 5 mg/kg, 1 times a day, continuous administration for 5 days. 2. Otitis media and pneumonia: Day 1 10 mg/kg administered at draught, a day of maximum amount does not exceed 500 mg; 2-5 day, a day 5 mg/kg administered at draught,a day of maximum amount does not exceed 250 mg. 3. Pharyngitis and tonsillitis: a day 12 mg/kg administered at draught, continuous administration for 5 days. A day of maximum amount does not exceed 500 mg. Administration can also refer to the following table. Children pharyngitis and tonsillitis (both 1 time a day) Weight Age three days administration plan five days administration plan 15kg or less 1-3years old once 100 mg, continuous administration for 3 days 15-25kg 3-8 years old  once 200 mg, continuous administration for 3 days.  first day once 200mg,2-5 days, once 100 mg 26-35kg 9-12 years old  once 300 mg, continuous administration for 3 days.  first day once 300mg,2-5 days, once 150 mg 36-45kg 13-15 years old  once 400 mg, continuous administration for 3 days.  first day once 400mg,2-5 days, once 200 mg 45kg or more Usage and dosage is same as adults.

Drug interactions

1. Azithromycin should not be taken with antacids containing aluminum or magnesium, which can be reduced by 30% of the peak plasma concentration of the product, but it has no impact on the overall bioavailability; If they must be combined the product should be administrated before one hour or after two hours taking these drugs. 2. When Azithromycin combines with theophylline, concentrations of theophylline in plasma will increase, and plasma theophylline levels should be noted. 3. When Azithromycin combines with warfarin, prothrombin time should be checked. 4. When Azithromycin and the following drugs are used at the same time, it is recommended to closely observe patients: Digoxin: there have been reports that some macrolide antibiotics can reduce the intestinal metabolism of digoxin. So using two drugs at the same time, it should be noted that plasma concentration of digoxin show a possibility to increase. Ergotamine or dihydroergotamine: Acute ergot toxicity, symptoms are severe peripheral vasospasm and hypoesthesia (dysesthesia). Triazolam: by reducing the degradation of triazolam, it can enhance pharmacological effects of triazolam. Cytochrome P450 system metabolite drug一 increasing serum levels of carbamazepine, terfenadine, cyclosporine, cyclohexanone, phenobarbital, phenytoin. 5. Azithromycin combined with rifabutin will increase toxicity of the latter.

Side effects

Patients are well tolerated to Azithromycin, incidence of adverse reactions is low. 1. Gastrointestinal: after treatment, fear of food, abdominal pain, diarrhea, nausea, vomiting, abdominal distension (<1%), gastritis (<1%), mucositis (<1%), pseudomembranous colitis, etc. can occur, butthe incidence was significantly lower than Erythromycin; small number of patients using the drug even can cause stomatitis, oral candidiasis (<1%); rare tongue discoloration. 2. Liver: alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase, bilirubin, alkaline phosphatase may increase transiently. The drug has been reported to cause hepatitis and cholestatic jaundice; occasionally cause liver necrosis and liver failure, but the relationship of rare death with the drug has not been determined. 3. Neuropsychiatric system: headache (<1%), drowsiness (<1%). In addition, the relationship of dizziness, convulsions, paresthesia, increased activity, aggressive reactions, nervousness, anxiety, anxiety with the drug has not been determined. 4. Allergies: fever, rash, itching may occur. Side effects which are associated with the drug have not been determined, including urticaria, bronchospasm (<1%), photosensitivity, joint pain. Anaphylactic shock and angioedema are extremely rare. Severe cases may occur erythema multiforme, Stevens-Johnson syndrome and toxic epidermal dissolve and necrosis. Drug should be discontinued immediately, and take appropriate measures. 5. Blood: may have the reduction of white blood cells, neutropenia, thrombocytopenia. 6. Urogenital system: common vaginitis; it may have a transient increase in serum creatinine; the relationship of existence of interstitial nephritis and acute renal failure with the drug has not been determined. 7. Ear: patients taking Azithromycin had been hearing impairment, including hearing loss, tinnitus and (or) epicophosis, which is related to high-dose use of the drug and mostly reversible. 8. Local: when the injection, injection site pain and local inflammation may occur. 9. Cardiovascular system: the relationship of cardiac arrhythmia, ventricular tachycardia with the drug has not been determined. 10. Other: it is reported rarely that drug causes changes in taste (<1%).

Precautions

1. Patients who are allergic to this product, Erythromycin or any other macrolide drug are contraindicated. 2. Application for pregnant women should be fully weighed; application for lactating women requires careful consideration; efficacy and safety for treatment of age <6 months of pediatric otitis media, community-acquired pneumonia and age <2 years pharyngitis or tonsillitis in children have not been determined. 3. Patients with mild renal insufficiency (creatinine clearance rate> 40ml/min) are no need for dose adjustments, but for more serious patients with renal insufficiency, should be used with caution. 4. Since the hepatobiliary system is the main route of excretion of the product, patients with liver dysfunction should be used with caution. Severe liver disease should not be used. Regular follow-up liver function during treatment. 5. Food can affect the absorption of Azithromycin, so oral administration is needed at 1h before meals or after meals 2h. 6. During the treatment if allergy occurs (such as angioneurotic edema, skin reactions, Stevens-Johnson syndrome and toxic epidermal necrolysis, etc.), patients should be discontinued immediately, and take appropriate measures. If patients appear diarrhea symptom, pseudomembranous colitis should be considered, if the diagnosis is determined, appropriate therapeutic measures should be took, including maintenance of water and electrolyte balance, proteins supplement, etc. 7. If suspected the combined anaerobic infectionsmerger anaerobic infections, Azithromycin should be combined with anti-anaerobic drugs during treatment of pelvic inflammatory disease.

Clinical evaluation

Foreign reports compared the Azithromycin with Cefaclor in treatment of acute lower respiratory tract infection. Azithromycin group had 191 cases, once daily for 5 consecutive days, the first time 0.5g, after each 0.25 g; Cefaclor group had 81 cases, once 0.5 g, 3 times a day for 10 consecutive days. Clinical cure and improvement rates in both groups were 96% and 94%, respectively, while the bacteriological clearance rate was 88%. In Huashan Hospital, Shanghai Medical University, 110 patients with respiratory tract infections were oral administration of the product, the total effective rate was 93.6%, bacterial clearance rate was 91.4%, the incidence of adverse reactions was 5.4%. The product has an excellent effect on the genitourinary system infections caused by Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma. Shanghai Dermatology Prevention Centre used this product to treat patients with non-gonococcal urethritis and gonorrhea, including 30 cases of chlamydia infection, 19 cases of mycoplasma infection, 28 cases of Neisseria gonorrhoeae infection, and oral administration, a single dose 1 g. The cure rates were 100%, 85%, 96.5%, respectively, and total effective rate was 100%. Previous studies suggested that as for people with high risk of cardiovascular, Azithromycin can increase the risk of cardiovascular mortality. But research in the real world population is lacked. Therefore, there is a large-scale population study in the real world. This is a 18-64-year-old national historical cohort study in Denmark, which is related to information including the prescription registration database, causes of death in patients, and general condition of the patient in 1997 to 2010, etc. The use of Azithromycin up to 110 million treatment courses and not use of antibiotics population controls (1: 1) were evaluated. In addition, compared with 7.36 million passengers using penicillin V (also based on propensity score matching), causes of death from cardiovascular were observed. The results showed that the use of Azithromycin and not use any antibiotics population significantly increased the risk of cardiovascular death (RR: 2.85, 95CI: 1.13-7.24). In the Azithromycin group, 17 patients died. In the penicillin V group, 146 patients died (RR: 0.93,95% CI: 0.56-1.55). Azithromycin does not increase the risk of cardiovascular death in young and elderly patients.

Chemical properties

White crystals. Melting point 113--115 ℃. [Α] D20-37 ° (C = 1, chloroform).

Uses

Macrolide antibiotic, 15-membered nitrogen-containing heterocyclic, antibacterial mechanism is similar to Erythromycin, but antibacterial spectrum is broader. The antibacterial activity of Gram-positive bacteria is stronger. As for Gram-negative bacteria such as Haemophilus influenzae, Salmonella, E. coli, Shigella bacteria, it have strong antibacterial activity. And it is acid stable and well tolerated. It has a very good therapeutic effect on respiratory tract infections, skin and soft tissue infections, sexually transmitted diseases which are caused by sensitive bacteria.

Production methods

Using Erythromycin A as raw material, after oximation, under the action of hydrochloric acid, Beckmann rearrangement is performed, followed by dehydration, reduction, methylation , and Azithromycin is obtained.

Description

Azithromycin is a macrolide antibiotic.1 It is active against S. pneumoniae, S. aureus, N. gonorrhoeae, M. pneumoniae, H. pylori, C. trachomatis, and H. influenzae in vitro (MIC90s = <0.01-2 mg/L). Azithromycin increases survival in mouse models of intraperitoneal S. pyogenes, S. pneumoniae, E. faecalis, or H. influenzae infection (ED50s = 0.78, 8.7, 12.7, and 30.3 mg/kg, respectively).2 It inhibits replication of severe acute respiratory coronavirus 2 (SARS-CoV-2), but not Middle East respiratory syndrome CoV (MERS-CoV), when used at concentrations of 5 and 10 μM.3 Azithromycin also decreases plasma levels of IL-6, TNF-α, and IL-1β and increases survival in a mouse model of LPS-induced sepsis when administered at a dose of 100 mg/kg.4 Formulations containing azithromycin have been used in the treatment of a variety of bacterial infections.

Description

Azithromycin is a long-acting macrolide antibiotic structurally related to erythromycin A (EA), having a methyl-substituted nitrogen at position 9a in the aglycone ring. Azithromycin is reported to be highly effective in the treatment of respiratory and urinary infections; it has the advantages of being acid-stable and requiring a shorter course of treatment than EA.

Chemical Properties

White Crystalline Powder

Originator

Pliva (Yugoslavia)

Uses

Labelled Azithromycin, a semi-synthetic macrolide antibiotic; related to Erythromycin A. Antibacterial.

Uses

Azithromycin is a semi-synthetic, ring-expanded erythromycin, produced by a Beckmann rearrangement of erythromycin oxime and reduction to the imine ether, followed by reductive methylation. Azithromycin was the first of the azalides and was designed to improve stability and biological half-life of erythromycin A, as well as improve activity against Gram negative bacteria. Since its discovery in 1980 by Djokic and co-workers, azithromycin has enjoyed considerable therapeutic success.

Uses

Cephalosporin antibiotic

Uses

Azithromycin is a semi-synthetic, ring-expanded erythromycin produced by a Beckmann rearrangement of erythromycin oxime and reduction to the imine ether, followed by reductive methylation. Azithromycin was the first of the azalides and was designed to improve the stability and biological half-life of erythromycin A, as well as improve activity against Gram negative bacteria. Since its discovery in 1980 by Djokic and co-workers, azithromycin has enjoyed considerable therapeutic success.

Uses

Labeled Azithromycin, Intended for use as an internal standard for the quantification of Azithromycin by GC- or LC-mass spectrometry

Definition

ChEBI: A macrolide antibiotic useful for the treatment of bacterial infections.

Indications

Azithromycin in a 500-mg dose three times a week has been shown to yield a 60% reduction in inflammatory papules in 83% of patients enrolled in a 12- week study. There is no associated pseudotumor cerebri and, therefore, it can be used for an acne flare during early Accutane therapy.

Manufacturing Process

To a solution of 0.54 g (0.000722 mole) of 11 aza-10-deoxo-10- dihydroerythromycin A in 20 ml CHCl3 were added 0.0589 ml (0.000741 mole) of formaldehyde (approx. 35% w./w.) and 0.00283 g (0.000735 mole) of formic acid (approx. 98 to 100% w./w.). The reaction mixture was stirred for 8 hours while heating under reflux, then cooled to ambient temperature, whereupon were added 15 ml of water (pH 5.8). The pH of the reaction mixture was adjusted to 5.0 by means of 2 N HCl, whereupon the CHCl3 layer was separated. To the aqueous part was added 15 ml of CHCl3, the pH of the reaction suspension was adjusted to 7.5 by means of 20% NaOH, the layers were separated and subsequently the aqueous layer was extracted three times with 15 ml of CHCl3. The combined chloroform extracts having pH 7.5 were dried over K2CO3 and evaporated under reduced pressure, yielding 0.45 g (82.4%) of N-methyl-11-aza-10-deoxo-10-dihydro erythromycin A (azithromycin), m.p. 113°-115°C. [α]D 20= - 37.0 (1% in CHCl3).

Brand name

Zithromax (Pfizer); Zmax (Pfizer);Sunamed.

Therapeutic Function

Antibiotic

Antimicrobial activity

It is less potent than erythromycin A against Gram-positive isolates, but is more active against Gram-negative bacteria. It is four times more potent than erythromycin A against H. influenzae, N. gonorrhoeae and Campylobacter spp., and twice as active against Mor. catarrhalis. It also exhibits superior potency against Enterobacteriaceae, notably Esch. coli, Salmonella enterica serotypes, and Shigella spp. It is active against Mycobacteria, notably the M. avium complex and against intracellular micro-organisms such as Legionella and Chlamydia spp.Chemical modification at the 9 position of the erythronolide A ring of erythromycin A blocks the internal ketalization and markedly improves acid stability. At pH 2, loss of 10% activity occurred in less than 4 s with erythromycin A, but took 20 min with azithromycin. The AUC at 0–24 h is 4.5 mg.h/L. The level is only slightly increased on repeated dosing.Binding to plasma protein varies with the concentration, from around 50% at 0.05 mg/L to 7.1% at 1 mg/L. The apparent elimination half-life is dependent upon sampling interval: between 8 and 24 h it ranged from 11 to 14 h; between 24 and 72 h it was 35–40 h.It rapidly penetrates the tissues, reaching levels that approach or, in some cases, exceed the simultaneous plasma levels and persist for 2–3 days. Only about 6% of the dose is found in urine in the first 24 h.

General Description

The spectrum of antimicrobial activity of azithromycin issimilar to that observed for erythromycin and clarithromycinbut with some interesting differences. In general,it is more active against Gram-negative bacteria and less activeagainst Gram-positive bacteria than its close relatives.The greater activity of azithromycin against H. influenzae,M. catarrhalis, and M. pneumoniae coupled with its extendedhalf-life permits a 5-day dosing schedule for thetreatment of respiratory tract infections caused by thesepathogens. The clinical efficacy of azithromycin in the treatmentof urogenital and other sexually transmitted infectionscaused by Chlamydia trachomatis, N. gonorrhoeae, H.ducreyi, and Ureaplasma urealyticum suggests that singledosetherapy with it for uncomplicated urethritis or cervicitismay have advantages over use of other antibiotics.

Pharmaceutical Applications

A semisynthetic derivative of erythromycin A, supplied as the dihydrate for oral administration.

Biological Activity

Macrolide antibiotic. Inhibits 50S ribosomal subunit formation and elongation at transpeptidation step in gram-positive and gram-negative organisms. Orally active with improved pharmacokinetics over erythromycin in mouse models.

Pharmacokinetics

Oral absorption:37% Cmax 250 mg oral: 0.17 mg/L after 2.2 h 500 mg oral: 0.4 mg/L after2h Plasma half-life (terminal): 11–40 hVolume of distribution: 31 L/kg Plasma protein binding :7–50%Chemical modification at the 9 position of the erythronolide A ring of erythromycin A blocks the internal ketalization and markedly improves acid stability. At pH 2, loss of 10% activity occurred in less than 4 s with erythromycin A, but took 20 min with azithromycin. The AUC at 0–24 h is 4.5 mg.h/L. The level is only slightly increased on repeated dosing.Binding to plasma protein varies with the concentration, from around 50% at 0.05 mg/L to 7.1% at 1 mg/L. The apparent elimination half-life is dependent upon sampling interval: between 8 and 24 h it ranged from 11 to 14 h: between 24 and 72 h it was 35–40 h.It rapidly penetrates the tissues, reaching levels that approach or, in some cases, exceed the simultaneous plasma levels and persist for 2–3 days. Only about 6% of the dose is found in urine in the first 24 h.

Clinical Use

Azithromycin is commonly the first choice for treatment of infections that require a macrolide.

Side effects

Azithromycin is well tolerated with little gastrointestinal disturbance.

Veterinary Drugs and Treatments

Azithromycin with its relative broad spectrum and favorable pharmacokinetic profile may be useful for a variety of infections in veterinary species. Little data is published at this time, however. Azithromycin has been shown to be ineffective in the treatment of Mycoplasma haemofelis in cats. Azithromycin may be potentially useful for treating Rhodococcus infections in foals.

Drug interactions

Potentially hazardous interactions with other drugs Anti-arrhythmics: increased toxicity with disopyramide; increased risk of ventricular arrhythmias with dronedarone - avoid. Antibacterials: possibly increased rifabutin concentration (increased risk of uveitis and neutropenia) - reduce dose of rifabutin. Anticoagulants: effect of coumarins may be enhanced. Antidepressants: the manufacturer of reboxetine advises to avoid concomitant use. Antihistamines: may inhibit the metabolism of mizolastine (risk of hazardous arrhythmias) - avoid. Antimalarials: avoid with artemether/lumefantrine; increased risk of ventricular arrhythmias with piperaquine with artenimol - avoid. Antipsychotics: increased risk of ventricular arrhythmias with droperidol - avoid. Antivirals: concentration possibly increased by ritonavir. Ciclosporin: may inhibit the metabolism of ciclosporin (increased ciclosporin levels). Colchicine: treatment with both agents has been shown in a study to increase the risk of fatal colchicine toxicity, especially in patients with renal impairment - avoid. Ergot alkaloids: increased risk of ergotism - avoid. Statins: possible increased risk of myopathy with atorvastatin and simvastatin.

Metabolism

In pharmacokinetic studies it has been demonstrated that the concentrations of azithromycin measured in tissues are noticeably higher (as much as 50 times) than those measured in plasma, which indicates that the agent strongly binds to tissues. Azithromycin is excreted in bile mainly as unchanged drug. Ten metabolites have also been detected in bile, which are formed through N- and O- demethylation in the liver, hydroxylation of desosamine - and aglycone rings and cleavage of cladinose conjugate. The metabolites of azithromycin are not microbiologically active
InChI:InChI=1/C38H72N2O12/c1-15-27-38(10,46)31(42)24(6)40(13)19-20(2)17-36(8,45)33(52-35-29(41)26(39(11)12)16-21(3)48-35)22(4)30(23(5)34(44)50-27)51-28-18-37(9,47-14)32(43)25(7)49-28/h20-33,35,41-43,45-46H,15-19H2,1-14H3/t20-,21-,22-,23-,24+,25-,26+,27+,28-,29-,30+,31-,32+,33+,35+,36-,37-,38+/m1/s1

83905-01-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name azithromycin

1.2 Other means of identification

Product number -
Other names Zifin

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:83905-01-5 SDS

83905-01-5Upstream product

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 83905-01-5